This activity is designed to educate hematologists, oncologists and other physicians about new advances in the diagnosis and treatment of all blood cancers. Through disease-specific lectures highlighting the most clinically relevant data presented at the ASH annual meeting, attendees will be able to identify and describe the emerging treatments available and utilize these treatments in their practice.
The American Society of Hematology (ASH) annual meeting in December is the event where cutting-edge therapeutic advances are presented publicly for the first time. Unfortunately, only a small fraction of professionals are able to attend this meeting. Therefore, it is vitally important for physicians and, in turn, their patients to have access to emerging data in a timely manner. At this one-day event, attendees will receive relevant updates on advances in acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myeloid leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, Waldenström's macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation, and CAR-T therapies.
Who should attend This course is intended for oncology and hematology physicians and residents, primary care physicians, nurses, physician assistants and nurse practitioners.
Important noteThe course will be taught entirely in English.
Learning objectives Upon completion of this activity, participants will be able to:
- Describe an overview and highlight recent medical advances presented at the American Society of Hematologists (ASH) annual meeting that will help physicians achieve better patient outcomes.
- Recognize appropriate management and treatment options for hematologic malignancies.
- Use these approaches in routine clinical practice.
- Review new therapies and approaches in non-malignant hematology.
Agenda 2025 Information for the 2026 course is not yet available. All agenda sessions are in Eastern Standard Time.
Saturday, February 8, 2025 9:00-9:10 AM Welcome and introduction Ann S. LaCasce, MD
9:10-9:50 AM ASH 2024: Transplant Highlights Mahasweta Gooptu, MD
9:50-10:30 AM ASH 2024: Highlights of ALL, CML and MPNs Daniel DeAngelo, MD, PhD
10:30-11:10 AM ASH 2024: Classical Hematology Highlights Nathan T. Connell, MD, MPH
11:10-11:50 AM ASH 2024: MDS and AML Richard M. Stone, MD
11:50 AM-12:05 PM 15-minute break
12:05-12:45 PM ASH 2024: CLL Highlights Inhye E. Ahn, MD
12:45-1:25 PM ASH 2024: Multiple Myeloma Highlights Shonali Midha, MD
1:25-2:05 PM ASH 2024: Lymphoma Highlights Jennifer L. Crombie, MD
2:05-2:45 PM ASH 2024: CAR-T Highlights Caron A. Jacobson, MD
2:45-2:55 PM Concluding remarks Ann S. LaCasce, MD
Reviews
There are no reviews yet.